Floatz logo

Omeprazole

Extrapyramidal And Movement Disease

University of California, Los AngelesSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Extrapyramidal And Movement Disease cohort.

Same molecule, other indications

Omeprazole is also rated in:

morbid obesityDormant
BB
Indicative · Phase 4
70 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative · Phase 2
64 / 100
View asset →
chemotherapy-induced neuropathyActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →